# EDGAR Filing Document

**Accession Number:** 0000019617
**File Stem:** 0001213900-25-092475
**Filing Date:** 2025-9
**Character Count:** 15768
**Document Hash:** f95e7614b8133806123b78092cefd40c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-092475.hdr.sgml**: 20250926

**ACCESSION NUMBER**: 0001213900-25-092475

**CONFORMED SUBMISSION TYPE**: FWP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250926

**DATE AS OF CHANGE**: 20250926

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JPMORGAN CHASE & CO
- **CENTRAL INDEX KEY:** 0000019617
- **STANDARD INDUSTRIAL CLASSIFICATION:** NATIONAL COMMERCIAL BANKS [6021]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 132624428
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-270004
- **FILM NUMBER:** 251351556

**BUSINESS ADDRESS:**
- **STREET 1:** 383 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 2122706000

**MAIL ADDRESS:**
- **STREET 1:** 383 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** J P MORGAN CHASE & CO
- **DATE OF NAME CHANGE:** 20010102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHASE MANHATTAN CORP /DE/
- **DATE OF NAME CHANGE:** 19960402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEMICAL BANKING CORP
- **DATE OF NAME CHANGE:** 19920703
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JPMORGAN CHASE & CO
- **CENTRAL INDEX KEY:** 0000019617
- **STANDARD INDUSTRIAL CLASSIFICATION:** NATIONAL COMMERCIAL BANKS [6021]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 132624428
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP

**BUSINESS ADDRESS:**
- **STREET 1:** 383 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 2122706000

**MAIL ADDRESS:**
- **STREET 1:** 383 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** J P MORGAN CHASE & CO
- **DATE OF NAME CHANGE:** 20010102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHASE MANHATTAN CORP /DE/
- **DATE OF NAME CHANGE:** 19960402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEMICAL BANKING CORP
- **DATE OF NAME CHANGE:** 19920703

**JPMorgan Chase Financial Company LLC**

Free Writing Prospectus Filed Pursuant to Rule 433

Registration Statement Nos. 333-270004 and 333-270004-01

Dated September 26, 2025

6yNC1y SX5E/SPX/TPX Jump Securities with Auto-Callable Feature

***This document provides a summary of the terms of the securities. Investors must carefully review the accompanying preliminary pricing supplement referenced below, product supplement, underlying supplement, prospectus supplement, prospectus and prospectus addendum and the "Risk Considerations" on the following page, prior to making an investment decision.***

---

| | |
|:---|:---|
| &nbsp;&nbsp;**SUMMARY TERMS** | &nbsp;&nbsp;**SUMMARY TERMS** |
| &nbsp;&nbsp;**Issuer:** | JPMorgan Chase Financial Company LLC ("JPMorgan Financial") |
| &nbsp;&nbsp;**Guarantor:** | JPMorgan Chase & Co. |
| &nbsp;&nbsp;**Underlying indices:** | EURO STOXX 50<sup>®</sup> Index (Bloomberg ticker: SX5E Index) (the "SX5E Index"), S&P 500<sup>®</sup> Index (Bloomberg ticker: SPX Index) (the "SPX Index") and TOPIX<sup>®</sup> Index (Bloomberg ticker: TPX Index) (the "TPX Index") (each, an "underlying index") |
| &nbsp;&nbsp;**Automatic early redemption:** | If, on any of the determination dates (other than the final determination date), the closing level of each underlying index is **greater than or equal to** its early redemption threshold level, the securities will be automatically redeemed for a cash payment equal to the early redemption payment payable on the applicable redemption date. |
| &nbsp;&nbsp;**Early redemption payment:** | The early redemption payment will be an amount equal to the stated principal amount *plus* an amount in cash per stated principal amount corresponding to a return of at least approximately 8.60% per annum (or at least 8.60% for the first determination date and increasing by at least 2.15% for each subsequent determination date), as follows: |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;1<sup>st</sup> determination date: | at least $1,086.00 |
| &nbsp;&nbsp;2<sup>nd</sup> determination date: | at least $1,107.50 |
| &nbsp;&nbsp;3<sup>rd</sup> determination date: | at least $1,129.00 |
| &nbsp;&nbsp;4<sup>th</sup> determination date: | at least $1,150.50 |
| &nbsp;&nbsp;5<sup>th</sup> determination date: | at least $1,172.00 |
| &nbsp;&nbsp;6<sup>th</sup> determination date: | at least $1,193.50 |
| &nbsp;&nbsp;7<sup>th</sup> determination date: | at least $1,215.00 |
| &nbsp;&nbsp;8<sup>th</sup> determination date: | at least $1,236.50 |
| &nbsp;&nbsp;9<sup>th</sup> determination date | at least $1,258.00 |
| &nbsp;&nbsp;10<sup>th</sup> determination date | at least $1,279.50 |
| &nbsp;&nbsp;11<sup>th</sup> determination date | at least $1,301.00 |
| &nbsp;&nbsp;12<sup>th</sup> determination date | at least $1,322.50 |
| &nbsp;&nbsp;13<sup>th</sup> determination date | at least $1,344.00 |
| &nbsp;&nbsp;14<sup>th</sup> determination date | at least $1,365.50 |
| &nbsp;&nbsp;15<sup>th</sup> determination date | at least $1,387.00 |
| &nbsp;&nbsp;16<sup>th</sup> determination date | at least $1,408.50 |
| &nbsp;&nbsp;17<sup>th</sup> determination date | at least $1,430.00 |
| &nbsp;&nbsp;18<sup>th</sup> determination date | at least $1,451.50 |
| &nbsp;&nbsp;19<sup>th</sup> determination date | at least $1,473.00 |
| &nbsp;&nbsp;20<sup>th</sup> determination date | at least $1,494.50 |
| The actual early redemption payment with respect to each applicable determination date will be provided in the pricing supplement. No further payments will be made on the securities once they have been redeemed. | The actual early redemption payment with respect to each applicable determination date will be provided in the pricing supplement. No further payments will be made on the securities once they have been redeemed. |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Payment at maturity:** | · If the final index value of each underlying index is **greater than or equal to its initial index value**: | the maturity redemption payment, which is an amount in cash per stated principal amount corresponding to a return of at least approximately 8.60% per annum, or at least $1,516.00. The actual maturity redemption payment will be provided in the pricing supplement. |
|  | · If the final index value of any underlying index is **less than** its initial index value: | (i) the stated principal amount *times* (ii) the index performance factor of the worst performing underlying index<br> **Under these circumstances, the payment at maturity will be less than the stated principal amount and could be zero.** |

---

---

| | |
|:---|:---|
| **Early redemption threshold level:** | With respect to each underlying index, 90% of its initial index value |
| **Initial index value:** | With respect to each underlying index, its closing level on the pricing date |
| **Final index value:** | With respect to each underlying index, its closing level on the final determination date<br>|

---

---

| | |
|:---|:---|
| **Worst performing underlying index:** | The underlying index with the worst index performance factor |
| **Index performance factor:** | With respect to each underlying index, its final index value *divided by* its initial index value |
| **Stated principal amount:** | $1,000 per security |
| **Issue price:** | $1,000 per security |
| **Pricing date:** | Expected to be September 30, 2025 |
| **Original issue date (settlement date):** | 3 business days after the pricing date |
| **Determination dates<sup>†</sup>:** | October 7, 2026, December 30, 2026, March 30, 2027, June 30, 2027, September 30, 2027, December 30, 2027, March 30, 2028, June 30, 2028, October 2, 2028, January 4, 2029, April 3, 2029, July 2, 2029, October 1, 2029, January 4, 2030, April 1, 2030, July 1, 2030, September 30, 2030, December 30, 2030, March 31, 2031, June 30, 2031 and September 30, 2031 (the final determination date) |
| &nbsp;&nbsp;**Redemption dates<sup>†</sup>:** | October 13, 2026, January 5, 2027, April 2, 2027, July 6, 2027, October 5, 2027, January 4, 2028, April 4, 2028, July 6, 2028, October 5, 2028, January 9, 2029, April 6, 2029, July 6, 2029, October 4, 2029, January 9, 2030, April 4, 2030, July 5, 2030, October 3, 2030, January 3, 2031, April 3, 2031, July 3, 2031 and the maturity date |
| &nbsp;&nbsp;**Maturity date<sup>†</sup>:** | October 3, 2031 |
| &nbsp;&nbsp;**CUSIP / ISIN:** | 48136HXT0 / US48136HXT03 |
| &nbsp;&nbsp;**Preliminary pricing supplement:** | [https://www.sec.gov/Archives/edgar/data/<br> 19617/000121390025092280/ea0259014-01_424b2.htm](https://www.sec.gov/Archives/edgar/data/19617/000121390025092280/ea0259014-01_424b2.htm) |

---

<sup>†</sup>Subject to postponement or early acceleration

The estimated value of the securities on the pricing date will be provided in the pricing supplement and will not be less than $920.00 per $1,000 stated principal amount security. For information about the estimated value of the securities, which likely will be lower than the price you paid for the securities, please see the hyperlink above.

Any payment on the securities is subject to the credit risk of JPMorgan Financial, as issuer of the securities, and the credit risk of JPMorgan Chase & Co., as guarantor of the securities.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Hypothetical Payout at Maturity** | &nbsp;&nbsp;**Hypothetical Payout at Maturity** |
| &nbsp;&nbsp;**Change in Worst Performing <br> Underlying Index** | &nbsp;&nbsp;**Payment at Maturity** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;50.00% | &nbsp;&nbsp;$1516.00 |
| &nbsp;&nbsp;40.00% | &nbsp;&nbsp;$1516.00 |
| &nbsp;&nbsp;30.00% | &nbsp;&nbsp;$1516.00 |
| &nbsp;&nbsp;20.00% | &nbsp;&nbsp;$1516.00 |
| &nbsp;&nbsp;10.00% | &nbsp;&nbsp;$1516.00 |
| &nbsp;&nbsp;5.00% | &nbsp;&nbsp;$1516.00 |
| &nbsp;&nbsp;0.00% | &nbsp;&nbsp;$1516.00 |
| &nbsp;&nbsp;-10.00% | &nbsp;&nbsp;$900.00 |
| &nbsp;&nbsp;-20.00% | &nbsp;&nbsp;$800.00 |
| &nbsp;&nbsp;-30.00% | &nbsp;&nbsp;$700.00 |
| &nbsp;&nbsp;-40.00% | &nbsp;&nbsp;$600.00 |
| &nbsp;&nbsp;-50.00% | &nbsp;&nbsp;$500.00 |
| &nbsp;&nbsp;-60.00% | &nbsp;&nbsp;$400.00 |
| &nbsp;&nbsp;-80.00% | &nbsp;&nbsp;$200.00 |
| &nbsp;&nbsp;-100.00% | &nbsp;&nbsp;$0.00 |

---

**JPMorgan Chase Financial Company LLC**

6yNC1y SX5E/SPX/TPX Jump Securities with Auto-Callable Feature

Underlying Indices

For more information about the underlying indices, including historical performance information, see the accompanying preliminary pricing supplement.

Risk Considerations

The risks identified below are not exhaustive. Please see "Risk Factors" in the accompanying prospectus supplement, product supplement and preliminary pricing supplement and Annex A to the accompanying prospectus addendum for additional information.

Risks Relating to the Securities Generally

▪ The securities do not pay interest or guarantee the return of any principal and your investment in the
securities may result in a loss.

▪ The appreciation potential of the securities is limited.

▪ You are exposed to the price risk of each underlying index.

▪ Because the securities are linked to the performance of the worst performing underlying index, you are
exposed to greater risks of no early redemption payment or maturity redemption payment and sustaining a loss on your investment than if
the securities were linked to just one underlying index.

▪ The securities are subject to the credit risks of JPMorgan Financial and JPMorgan Chase & Co.,
and any actual or anticipated changes to our or JPMorgan Chase & Co.'s credit ratings or credit spreads may adversely
affect the market value of the securities.

▪ As a finance subsidiary, JPMorgan Financial has no independent operations and has limited assets.

▪ Investors will not participate in any appreciation of any underlying index.

▪ Early redemption risk.

▪ Secondary trading may be limited.

▪ We may accelerate your securities in our sole discretion and the calculation agent may adjust their final
payment in good faith and in a commercially reasonable manner if a change-in-law event occurs.

▪ The final terms and estimated valuation of the securities will be provided in the pricing supplement.

▪ The tax consequences of an investment in the securities are uncertain.

Risks Relating to Conflicts of Interest

▪ Economic interests of the issuer, the guarantor, the calculation agent, the agent of the offering of
the securities and other affiliates of the issuer may be different from those of investors.

▪ Hedging and trading activities by the issuer and its affiliates could potentially affect the value of
the securities.

Risks Relating to the Estimated Value and Secondary Market Prices of the Securities

▪ The estimated value of the securities will be lower than the original issue price (price to public) of
the securities .

▪ The estimated value of the securities does not represent future values of the securities and may differ
from others' estimates.

▪ The estimated value of the securities
is derived by reference to an internal funding rate.

▪ The value of the securities as published
by J.P. Morgan Securities LLC (and which may be reflected on customer account statements) may be higher than the then-current estimated
value of the securities for a limited time period.

▪ Secondary market prices of the securities will likely be lower than the original issue price of the securities .

▪ Secondary market prices of the securities
will be impacted by many economic and market factors.

Risks Relating to the Underlying Indices

▪ JPMorgan Chase & Co. is currently one of the companies that make up the SPX Index.

▪ Investing in the securities is not equivalent to investing in any underlying index.

▪ Adjustments to any underlying index could adversely affect the value of the securities.

▪ The securities are subject to risks associated with securities issued by non-U.S. companies with respect
to the SX5E Index and the TPX Index.

▪ The securities are not directly exposed to fluctuations in foreign exchange rates with respect to the
SX5E Index and the TPX Index.

▪ Governmental legislative and regulatory actions, including sanctions, could adversely affect your investment
in the securities.

Tax Considerations

You should review carefully the discussion in the accompanying preliminary pricing supplement under "Additional Information about the Securities — Tax considerations" concerning the U.S. federal income tax consequences of an investment in the securities, and you should consult your tax adviser.'

SEC Legend: JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. have filed a registration statement (including a prospectus) with the SEC for any offerings to which these materials relate. Before you invest, you should read the prospectus in that registration statement and the other documents relating to this offering that JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. has filed with the SEC for more complete information about JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. and this offering. You may get these documents without cost by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co., any agent or any dealer participating in the this offering will arrange to send you the prospectus and each prospectus supplement as well as any product supplement, underlying supplement and preliminary pricing supplement if you so request by calling toll-free 1-866-535-9248.